Paradigm Biopharmaceuticals Ltd (ASX:PAR) is an Australian biopharmaceutical company focused on repurposing the drug pentosan polysulphate sodium (PPS) for the treatment of inflammation.
Paradigm Shift
Repurposing
Established drugs can be repurposed for new clinical indications for unmet medical needs when protected by strong intellectual property. Historical drug safety data and existing manufacturing ‘know-how’ can fast-track clinical development and reduce commercialisation costs for repurposed drugs.
Understanding complexity
Life is complex! For every diagnosis, there are multiple factors and biological interactions involved. We develop therapeutics targeting multiple pathways involved in injury or on the road to disease producing better outcomes for patients.
We develop therapeutics targeting multiple pathways involved in injury
Our focus
Pentosan Polysulphate Sodium (PPS)
We focus on PPS because this FDA approved drug has a long history of safety and efficacy in treating interstitial cystitis and deep vein thrombosis. Our patents cover new applications in bone marrow edema (BME) and respiratory disease.
Inflammation
Inflammation is a complex biological response to injury, infection or allergy, which has short and long term components mediated by factors produced by immune cells.
Paradigm provides regulatory filing update
25th October 2019
Paradigm is pleased to report the Institutional Review Board (IRB) submission to treat the 10 patients (ex-NFL players) under the FDA approved EAP has also been cleared and approved…
Paradigm's end of year Calendar Update
12th December 2019
Paradigm Biopharmaceuticals Ltd is pleased to present an update on its business and clinical development programs…
Inflammation is a complex biological response to injury, infection or allergy
Key Statistics
Alpharirus
Alphaviruses, including Ross River virus (RRv) and Chikungunya (CHIKV) are mosquito-transmitted arthritogenic alphaviruses that cause epidemics of severe musculoskeletal disease.
*Simon, Fabrice et al. “Chikungunya Virus Infection.” Current Infectious Disease Reports 13.3 (2011): 218–228. PMC. Web. 10 Oct. 2016
Osteoarthritis (OA)
OA is a condition with a significant unmet medical need. Opioid abuse resulting from mismanagement of pain is a major problem in the US and most western countries.
*National Institute of Health; Emerging drugs for osteoarthritis; Hunter DJ and Matthews G 16(3): 479–491; 2011 September
Bone Marrow Edema (BME)
Worldwide hip & knee surgical implant market is $16.7 billion, will be $33 billion by 2022. Acute joint injury leads to osteoarthritis.
Bone Marrow Edema (BME)
>50% top ranked skiers have injured knee ligaments (women 5x more susceptible than men)
Research & Development
Paradigm is evaluating new intellectual property that has relevance to treating inflammation, especially in orthopaedics.